Back to your search result

Description

A cell-permeable tetrahydroquinoline based compound that acts as a highly potent and selective inhibitor of bromodomain and extra-terminal (BET) family proteins (IC50 = 41, 31, and 22 nM for BRD2, BRD3, BRD4, respectively). Binds to the acetyl-lysine recognition pocket of BET proteins and competes with tetra-acetylated histone H4 peptides (K5ac, K8ac, K12ac, K16ac) for binding to the bromodomains of these proteins. Does not affect the activity of over 50 different receptors, ion channels, and transporters even at higher concentrations (1-10 µ,M). Exhibits cytotoxicity towards neuroblastoma cell lines, induces apoptosis, and inhibits their growth (gIC50 = 26 and 60 nM for CHP-212 and SK-N-AS cells, respectively). Suppresses the growth of human neuroblastoma xenografts in murine models (5 mg/kg, p.o. for 2 weeks) and reduces the expression of MYCN and BCL2. Shown to improve survival rate of Balb/c mice subjected to LPS-induced (15 - 20 mg/kg) septic shock (10 mg/kg, i.v.). Displays desirable pharmacokinetic properties (t1/2 = 3.6 h, AUC 0-t = 6.03 µ,g/h/ml at 10 mg/kg i.v. in mice)., BET Inhibitor, I-BET726, is a cell-permeable, potent, and selective inhibitor of BET family proteins (IC₅,₀, = 41, 31, and 22 nM for BRD2, BRD3, BRD4, respectively)., A cell-permeable tetrahydroquinoline based compound that acts as a highly potent and selective inhibitor of bromodomain and extra-terminal (BET) family proteins (IC50 = 41, 31, and 22 nM for BRD2, BRD3, BRD4, respectively). Binds to the acetyl-lysine recognition pocket of BET proteins and competes with tetra-acetylated histone H4 peptides (K5ac, K8ac, K12ac, K16ac) for binding to the bromodomains of these proteins. Does not affect the activity of over 50 different receptors, ion channels, and transporters even at higher concentrations (1-10 µ,M). Exhibits cytotoxicity towards neuroblastoma cell lines, induces apoptosis, and inhibits their growth (gIC50 = 26 and 60 nM for CHP-212 and SK-N-AS cells, respectively). Suppresses the growth of human neuroblastoma xenografts in murine models (5 mg/kg, p.o. for 2 weeks) and reduces the expression of MYCN and BCL2. Shown to improve survival rate of Balb/c mice subjected to LPS-induced (15 - 20 mg/kg) septic shock (10 mg/kg, i.v.). Displays desirable pharmacokinetic properties (t1/2 = 3.6 h, AUC 0-t = 6.03 µ,g/h/ml at 10 mg/kg i.v. in mice).Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.